New ALS treatment appears to slow disease progression

Advocates are now calling on the FDA to speed up the drug’s approval.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is an incurable neurological disorder that affects a person’s voluntary muscle movement.

ALS is progressive — the longer a person has it, the worse it gets. In the disease’s final stages, patients lose their ability to move or speak, and most will die within just five years of developing symptoms.

To date, the U.S. Food and Drug Administration (FDA) has approved just two treatments for ALS.

Now, a third ALS treatment has shown promise in a Phase 2 clinical trial — and experts are petitioning the agency to skip the next trial phase and make the drug available to patients as soon as possible.

A New ALS Treatment

The new ALS treatment is a combination of two drugs: a supplement (taurursodiol) and a medication used to treat a pediatric urea disorder (sodium phenylbutyrate).

The drugs each target a different cell structure, and in 2013, Joshua Cohen, co-founder of Amylyx Pharmaceuticals, came up with the idea to combine the two to treat brain disorders.

To see whether the drug combo might help ALS patients, Amylyx teamed up with researchers at Massachusetts General Hospital for a Phase 2 trial, publishing its results in the New England Journal of Medicine on September 3.

The researchers gave two-thirds of the 137 trial participants daily doses of the new ALS treatment, and the other third a placebo.

They then used the ALS Functional Rating Scale — a questionnaire focused on patients’ abilities to do common daily activities, such as walking and swallowing food — to evaluate the participants’ ALS progression over the course of the six-month study.

A score of 48 on that scale indicates totally normal motor function, and as a person’s physical abilities deteriorate, their score drops. Over the course of the trial, the scores of the patients who received the placebo lowered about 2 points more than those who received the new ALS treatment.

Improving Quality of Life

A two-point difference in questionnaire scores might not seem like much, but for ALS patients, it can indicate a dramatic difference in quality of life.

“That can mean the difference between being able to feed yourself versus being fed or not needing a wheelchair versus needing a wheelchair,” Neil Thakur, chief mission officer of the ALS Association, a nonprofit that helped pay for the study, told the New York Times.

With a typical survival time of between 2 to 5 years, people with ALS cannot wait.

ALS Association and I Am ALS

In other areas of measurement (such as muscle strength and respiratory ability), the new treatment appeared to provide benefits to the participants although these results were not statistically significant.

Most of the participants in the study were already taking at least one of the drugs already approved for ALS. Still, researchers believe the new ALS treatment provided additional benefits and that the new treatment could be taken alongside existing medications.

“The data that we see here indicates there may be some beneficial effect but it doesn’t look like what you’d call a home run,” Dr. Koroshetz, director of the National Institute of Neurological Disorders and Stroke, who was not involved in the study told the New York Times.

Some patients that received the treatment experienced nausea, diarrhea, and other gastrointestinal side effects for about three weeks, but overall, the drug was safe, the researchers reported.

Slowing ALS Progression ASAP

Normally, the next step in the development of any new ALS treatment would be a larger Phase 3 trial, which would take several more years.

But the ALS Association and I Am ALS, a nonprofit ALS patient-advocacy group, have launched a petition asking the FDA to skip that phase and make the new treatment available to patients as soon as possible.

There’s some precedent to this: certain cancer drugs have been approved in mid-stage trials for patients in critical need of treatment.

“With a typical survival time of between 2 to 5 years, people with ALS cannot wait for the full experimental process for (the treatment) to continue,” the petition reads. “We are asking the FDA and Amylyx to work together to bring (the treatment) to people with ALS as soon as possible.”

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

Revolutionary weight-loss drugs like Wegovy come with a catch
People taking GLP-1 agonists are losing too much muscle, but these drugs designed to prevent muscle loss could solve the problem.
Are weight-loss meds the next wonder drugs?
Evidence is mounting that GLP-1 agonists could treat many health issues — including ones that aren’t obviously related to weight.
What hybrid mouse/rat brains are showing us about the mind
Modified mice with hybrid brains that include rat neurons could one day lead to new breakthroughs in neuroscience.
Milk could overcome one of the biggest hurdles to RNA therapies
RNA therapies typically break down if administered orally, but particles found in cows’ milk could provide perfect protection.
How sensory gamma rhythm stimulation clears amyloid in Alzheimer’s mice
Study finds stimulating a brain rhythm with light and sound increases peptide release from interneurons, possibly slowing Alzheimer’s progression.
Up Next
Drug Delivery
Subscribe to Freethink for more great stories